Profile avatar
drrichjlaw.bsky.social
Former Chief Business Officer at Exscientia, now Recursion $RXRX. About to start something new & super exciting! Deal maker, drug inventor, biotech builder, PhD computational chemist, bike racer, ex-Oxford rower & LFC fan! #YNWA.
144 posts 859 followers 161 following
Prolific Poster
Conversation Starter

Achira, backed by Nvidia, launches with $33M to use AI and physics in molecular modeling for drug discovery.

Dear $HIMS, The FDA says Ozempic, Wegovy shortage is officially over! endpts.com/fda-says-oze...

Peter Guenter will retire as CEO of Merck KGaA’s healthcare business and CMO Danny Bar-Zohar will replace him. endpts.com/merck-kgaa-t...

This is a really good long read on the challenges & missteps of the CRISPR therapeutics field. Ultimately the technology is best suited to monogenic rare disease, but the economics of the whole field have to get there first. by Ryan Cross👏 @endpts.com endpts.com/biotech-is-s...

If you're wondering about if this important vaccine advisory committee meeting is still happening, it's not. @helenbranswell.bsky.social with the scoop www.statnews.com/2025/02/20/a...

BridgeBio’s heart disease drug Attruby sails past prescription estimates. $BBIO 👏 endpts.com/bridgebios-h...

As @dereklowe.bsky.social was asking, we need more pharma CEOs to speak up! Merck, Pfizer, Lilly, Amgen - where are your voices?! (BTW- really read to the bottom of this).

Please share: The Committee on Science, Space, and Technology, Democratic Staff, is surveying the impact of the Trump Admin’s mass firings of federal employees from science agencies. If you were terminated since 20 Jan 2025 please fill out this survey: democrats-science.house.gov/sciencefirings

Bravo to Recursion, and Chris Gibson in particular, for speaking out against the utterly nihilistic self-destruction of the edifice of American science. I hope others will join his voice and speak truth to cowards

"Altitude Lab Fund intends to invest ... $100,000 to $250,000 in pre-seed capital, plus a grant of 12 months of lab and office space, and admission to Altitude Lab’s competitive accelerator program" #startups #FundingFreeze

As @dereklowe.bsky.social was asking, we need more pharma CEOs to speak up! Merck, Pfizer, Lilly, Amgen - where are your voices?! (BTW- really read to the bottom of this).

I lost my job at the National Science Foundation yesterday, along with 167 of my colleagues, including some dear friends. This was the best job I've ever had, and I thought it would be my last. The PI community has been sympathetic and supportive, without exception. I will miss working for you.

Recursion CEO Chris Gibson: Publicly funded research built the biopharma industry. Now it needs our help. Companies with resources must bridge the gap. 👏 $RXRX via @statnews.com www.statnews.com/2025/02/19/n...

Atomwise hires former eFFECTOR Therapeutics biotech vet as CEO amid revealing $45M series C raise & preclinical Tyk2 molecule progress. via @endpts.com endpts.com/exclusive-ai...

BioNTech vets Shanshan Zu & Helmut Jeggle raise $90M Series A for bispecific I&I startup Bambusa Therapeutics; endpts.com/biontech-vet... @endpts.com

Rallybio being valued at just $30M for the whole company is absolutely nuts! $RLYB There are so many disjunctions in this market at the moment - in both directions! $XBI

We've lost a computational chemistry giant! Prof Graham Richards was a leading light for the whole field and a mentor to many! 👏😢 royalsociety.org/people/graha...

Ex-DeepMind scientist Simon Kohl raises $50M & launches AI drug discovery venture Latent Labs, intending to service pharma with GenAI - on.ft.com/4hCJamw

[Biopharma need to] Stand Up and Be Counted. www.science.org/content/blog...

Novartis buys Blackstone's Anthos Therapeutics for up to $3.1Bn ($925M upfront, $2.15Bn in m/s). www.reuters.com/markets/deal...

Arm’s CEO on the future of AI and why he does not fear DeepSeek - on.ft.com/4jOrm9v

The UK university sector has its problems, but at least it’s not deliberately being destroyed

The cuts at BMS just keep on cutting. www.fiercebiotech.com/biotech/bris...

Like an episode of Shogun, Bain buys 340-year-old Japanese pharma company Tanabe to fast-track Japan’s drug development - on.ft.com/3XeWfuf

The inside story of UK government failure to clinch AstraZeneca vaccine manufacturing plant deal - basically due lack of NICE Enhertu approval & Labour DOGE on the £90M promised but not DD'd investment. on.ft.com/42MCAFf

Insitro quietly exits oncology.

Lung cancer in people who have never smoked is now estimated to be the fifth highest cause of cancer deaths worldwide. www.theguardian.com/society/2025...

Airstreet with $3M day one investment into Fern Labs to build multi-agent systems for real-world problems. @airstreet press.airstreet.com/p/our-invest...

“Everyone I know in public health and science more broadly is freaking out right now.” Datasets are disappearing off of the CDC website (and we're hearing rumors that there will likely be more by the end of the day) by @theresagaff.bsky.social at @statnews.com www.statnews.com/2025/01/31/c...

If you work in drug discovery and you read one thing this weekend, make it this exceptional J Med Chem editorial. Hits on almost every blessed thing I’ve tweetorialized over the last several years. Quantitation and Error Measurements in Dose–Response Curves

Guinea has wiped out sleeping sickness – will the rest of Africa follow? (via the DNDi & Anacor's development & supply of the new treatments; acoziborole & NECT (Nifurtimox-eflornithine combination therapy)); www.telegraph.co.uk/global-healt...

Acellera and Psivant Collaborate to Develop Transformative Computational Drug Discovery Approaches Using AI and Quantum Simulations www.acellera.com/blog/aceller...

GSK signs £50m deal with Oxford University on cancer vaccines. Collaboration over at least three years aims to help understand how pre-cancerous cells develop. www.theguardian.com/business/202...

I want to share some personal news with you all. After an incredible 4+ years with Exscientia (now Recursion), I have decided to move on to new adventures. ⛰️ (1/7)

👋🙏🐟

$GILD paying $250M upfront for LEO Pharma’s preclinical STAT6 portfolio. Talk about a hot target #JPM25 www.businesswire.com/news/home/20...